.
.

Continuing Education Activities

Here at JADPRO CE, you can find a valuable array of accredited educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!

Topic

Format

      Quick Tips →

*Sorted by program start date
NSCLC
Print

Understanding the Role of Targets and Pathways in the Treatment of Non–Small Cell Lung Cancer

 Lung cancer is the leading cause of cancer-associated mortality and late diagnosis is a fundamental obstacle to improving outcomes in lung cancer, exacerbating the unmet medical need for APs to maintain a continually high educational status about increasingly complex diagnostics and treatment options. This activity will provide education to assist APs in closing or narrowing this medical gap, providing a better understanding of the use of targeted and immunotherapies as they apply to the management of NSCLC.

Posted: 7/18/2017 / Expires: 7/18/2018

Credits/Contact Hours: 3.0

CAR-T
Print

The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias

The development of tumor-targeted chimeric antigen receptor (CAR)–modified T cells has demonstrated the potential of this therapy for certain patients with refractory or relapsed leukemias and lymphomas. This article discusses the design of first- and second-generation CARs, their proposed MOAs, and key associated toxicities. As clinical use of this technology progresses, advanced practitioners will need to understand the biology underlying CAR T-cell therapy and play crucial roles in managing treatment-related toxicities.

 

Posted: 9/12/2017 / Expires: 9/11/2018

Credits/Contact Hours: 1.0

GYNECOLOGIC ONCOLOGY
Print

Genetic Counseling in Gynecologic Oncology: What Advanced Practitioners Need to Know

The genetic predisposition to cancer and the advent of targeted therapy ushered in the growth of genetic testing and genetic counseling in oncology. Because of this, genetic counseling is strongly recommended. It is therefore expected that advanced practitioners, who are on the forefront of oncology patient care, play a key role in genetic counseling by developing an expertise through advancing their education and practice.

Posted: 10/17/2017 / Expires: 10/16/2018

Credits/Contact Hours: 1.5

MOLECULAR TESTING
Print

The Emerging Role of Molecular Testing in Non–Small Cell Lung Cancer

A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of non–small cell lung cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy. 

Posted: 10/19/2017 / Expires: 10/18/2018

Credits/Contact Hours: 1.0

MOLECULAR TESTING
Print

The Emerging Role of Molecular Testing in Ovarian Cancer

 A rapidly emerging concept that holds the promise of altering the natural history and subsequently outcomes for cancer patients is that of precision—or personalized—medicine. There is an immediate and growing need to alert advanced practitioners about the role molecular profiling has in the treatment of ovarina cancer, from a primarily prognostic role to one that can also provide predictive guidance regarding the choice of a specific therapy. 

Posted: 10/19/2017 / Expires: 10/18/2018

Credits/Contact Hours: 1.0

BIOSIMILARS
Print

Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner

Over the past two decades, biologics have had a huge impact on the treatment of cancer in multiple tumor types, and in many cases these agents have improved outcomes and survival. In oncology, a growing number of biosimilars have been approved and are in clinical use, with more in the FDA pipeline.

Posted: 11/16/2017 / Expires: 11/16/2018

Credits/Contact Hours: 0.75

ORAL ONCOLYTICS
Print

The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics

Almost 40% of the total cost of targeted therapies in the US are now for oral formulations, up from 26% in 2010. This increase calls for APs to act as practice-to-patient liaison with limited resources.  This education will focus on how APs can overcome a variety of barriers for patient nonadherence to oral therapies and encourage patients to continue their regimens. 

Posted: 12/8/2017 / Expires: 12/7/2018

Credits/Contact Hours: 1.0

CHRONIC LYMPHOCYTIC LEUKEMIA
Print

Understanding the Role of Targets and Pathways in the Treatment of Chronic Lymphocytic Leukemia

CLL is the most common leukemia in Western countries, with a  population primarily over 70 years of age. Frailty and comorbidities are common concerns with established chemoimmunotherapy, but new FDA-approved therapies have led to specialized, specific treatments for the different stages of CLL. 

Posted: 12/19/2017 / Expires: 12/18/2018

Credits/Contact Hours: 3.0

Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.